Reyvow vs. Ajovy

• Are Reyvow and Ajovy the Same Thing?
• What Are Possible Side Effects of Reyvow?
• What Are Possible Side Effects of Ajovy?
• What Is Reyvow?
• What Is Ajovy?
• What Drugs Interact with Reyvow?
• What Drugs Interact with Ajovy?
• How Should Reyvow Be Taken?
• How Should Ajovy Be Taken?

Reyvow (lasmiditan) and Ajovy (fremanezumab-vfrm) Injection are used to prevent or treat migraine.

Reyvow is used for the acute treatment of migraine with or without aura in adults. Reyvow is not indicated for the preventive treatment of migraine.

Ajovy is indicated for the preventive treatment of migraine in adults.

Reyvow and Ajovy belong to different drug classes. Reyvow is a serotonin (5-HT) 1F receptor agonist and Ajovy is a calcitonin gene-related peptide receptor antagonist.

Side effects of Reyvow that are different from Ajovy include dizziness, fatigue, numbness and tingling, sedation, nausea, and vomiting.

Side effects of Ajovy that are different from Reyvow include injection site reactions (pain, swelling, and redness).

Reyvow may interact with alcohol or other CNS depressants, antidepressants, MAO inhibitors, trazodone, dextromethorphan, St. John's wort, medications that lower heart rate, and P-gp or BCRP substrates.

Ajovy may interact with other drugs.

Common side effects of Reyvow include:

• dizziness,
• fatigue,
• numbness and tingling,
• sedation,
• nausea, and
• vomiting

Common side effects of Ajovy include:

• injection site reactions (pain, swelling, and redness)

Reyvow (lasmiditan) is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults. Reyvow is not indicated for the preventive treatment of migraine.

Ajovy (fremanezumab-vfrm) is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults.

Reyvow may interact with:

• alcohol or other CNS depressants,
• antidepressants,
• MAO inhibitors,
• trazodone,
• dextromethorphan,
• St. John's wort,
• medications that lower heart rate, and
• P-gp or BCRP substrates

Ajovy may interact with other drugs. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Ajovy; it is unknown how it would affect a fetus. It is unknown if Ajovy passes into breast milk. Consult your doctor before breastfeeding.

The recommended dose of Reyvow is 50 mg, 100 mg, or 200 mg taken orally, as needed. No more than one dose of Reyvow should be taken in 24 hours.

Two subcutaneous dosing options of Ajovy are available to administer the recommended dosage: 225 mg monthly, or 675 mg every 3 months (quarterly). The 675 mg quarterly dosage is administered as three consecutive injections of 225 mg each.